370 related articles for article (PubMed ID: 28150186)
1. Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial.
Filippatos G; Farmakis D; Metra M; Cotter G; Davison BA; Felker GM; Greenberg BH; Hua TA; Pang PS; Ponikowski P; Qian M; Severin TA; Voors AA; Teerlink JR
Clin Res Cardiol; 2017 Jun; 106(6):444-456. PubMed ID: 28150186
[TBL] [Abstract][Full Text] [Related]
2. Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence.
Ghosh RK; Banerjee K; Tummala R; Ball S; Ravakhah K; Gupta A
Cardiovasc Ther; 2017 Feb; 35(1):55-63. PubMed ID: 27727514
[TBL] [Abstract][Full Text] [Related]
3. Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF.
Liu LC; Voors AA; Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Chen Y; Greenberg BH; Ponikowski P; Pang PS; Prescott MF; Hua TA; Severin TM; Metra M
Clin Res Cardiol; 2016 Sep; 105(9):727-37. PubMed ID: 27017514
[TBL] [Abstract][Full Text] [Related]
4. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.
Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld LR; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin TM; Metra M;
Lancet; 2013 Jan; 381(9860):29-39. PubMed ID: 23141816
[TBL] [Abstract][Full Text] [Related]
5. Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial.
Filippatos G; Teerlink JR; Farmakis D; Cotter G; Davison BA; Felker GM; Greenberg BH; Hua T; Ponikowski P; Severin T; Unemori E; Voors AA; Metra M
Eur Heart J; 2014 Apr; 35(16):1041-50. PubMed ID: 24316514
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard Therapy in Asian Patients With Acute Heart Failure: Design and Rationale of RELAX-AHF-ASIA Trial.
Sato N; Lam CS; Teerlink JR; Greenberg BH; Tsutsui H; Oh BH; Zhang J; Lefkowitz M; Hua TA; Holbro T; Marshood M; Wang XL; Ge J
J Card Fail; 2017 Jan; 23(1):63-71. PubMed ID: 27825893
[TBL] [Abstract][Full Text] [Related]
7. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.
Metra M; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld L; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Prescott MF; Edwards C; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin T; Teerlink JR;
J Am Coll Cardiol; 2013 Jan; 61(2):196-206. PubMed ID: 23273292
[TBL] [Abstract][Full Text] [Related]
8. Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study.
Felker GM; Teerlink JR; Butler J; Hernandez AF; Miller AB; Cotter G; Davison BA; Filippatos G; Greenberg BH; Ponikowski P; Voors AA; Hua TA; Severin TM; Unemori E; Metra M
J Am Coll Cardiol; 2014 Oct; 64(15):1591-8. PubMed ID: 25301463
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU.
Maggioni AP; López-Sendón J; Nielsen OW; Hallén J; Aalamian-Mattheis M; Wang Y; Ertl G
Eur J Heart Fail; 2019 Mar; 21(3):322-333. PubMed ID: 30604559
[TBL] [Abstract][Full Text] [Related]
10. Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial.
Pang PS; Teerlink JR; Boer-Martins L; Gimpelewicz C; Davison BA; Wang Y; Voors AA; Severin T; Ponikowski P; Hua TA; Greenberg BH; Filippatos G; Felker GM; Cotter G; Metra M
Am Heart J; 2017 May; 187():62-69. PubMed ID: 28454809
[TBL] [Abstract][Full Text] [Related]
11. Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure.
Sato N; Takahashi W; Hirayama A; Ajioka M; Takahashi N; Okishige K; Wang X; Maki A; Maruyama H; Ebinger U; Yamaguchi M; Pang Y; Matsumoto H; Kawana M
Circ J; 2015; 79(6):1237-47. PubMed ID: 25912697
[TBL] [Abstract][Full Text] [Related]
12. Serelaxin : a potential new drug for the treatment of acute heart failure.
Neverova N; Teerlink JR
Expert Opin Investig Drugs; 2014 Jul; 23(7):1017-26. PubMed ID: 24865798
[TBL] [Abstract][Full Text] [Related]
13. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study.
Teerlink JR; Voors AA; Ponikowski P; Pang PS; Greenberg BH; Filippatos G; Felker GM; Davison BA; Cotter G; Gimpelewicz C; Boer-Martins L; Wernsing M; Hua TA; Severin T; Metra M
Eur J Heart Fail; 2017 Jun; 19(6):800-809. PubMed ID: 28452195
[TBL] [Abstract][Full Text] [Related]
14. Effects of Serelaxin in Patients with Acute Heart Failure.
Metra M; Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Voors AA; Adams KF; Anker SD; Arias-Mendoza A; Avendaño P; Bacal F; Böhm M; Bortman G; Cleland JGF; Cohen-Solal A; Crespo-Leiro MG; Dorobantu M; Echeverría LE; Ferrari R; Goland S; Goncalvesová E; Goudev A; Køber L; Lema-Osores J; Levy PD; McDonald K; Manga P; Merkely B; Mueller C; Pieske B; Silva-Cardoso J; Špinar J; Squire I; Stępińska J; Van Mieghem W; von Lewinski D; Wikström G; Yilmaz MB; Hagner N; Holbro T; Hua TA; Sabarwal SV; Severin T; Szecsödy P; Gimpelewicz C;
N Engl J Med; 2019 Aug; 381(8):716-726. PubMed ID: 31433919
[TBL] [Abstract][Full Text] [Related]
15. Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2.
Loungani RS; Teerlink JR; Metra M; Allen LA; Butler J; Carson PE; Chen CW; Cotter G; Davison BA; Eapen ZJ; Filippatos GS; Gimpelewicz C; Greenberg B; Holbro T; Januzzi JL; Lanfear DE; Pang PS; Piña IL; Ponikowski P; Miller AB; Voors AA; Felker GM
JACC Heart Fail; 2020 Dec; 8(12):999-1008. PubMed ID: 33189635
[TBL] [Abstract][Full Text] [Related]
16. Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin.
Schmieder RE; Mitrovic V; Hengstenberg C
Clin Res Cardiol; 2015 Aug; 104(8):621-31. PubMed ID: 25787721
[TBL] [Abstract][Full Text] [Related]
17. Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF.
Metra M; Ponikowski P; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Hua TA; Severin T; Unemori E; Voors AA; Teerlink JR
Eur Heart J; 2013 Oct; 34(40):3128-36. PubMed ID: 23999454
[TBL] [Abstract][Full Text] [Related]
18. Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection.
Díez J; Ruilope LM
Eur Heart J Cardiovasc Pharmacother; 2016 Apr; 2(2):119-30. PubMed ID: 27418970
[TBL] [Abstract][Full Text] [Related]
19. Serelaxin and acute heart failure.
Tietjens J; Teerlink JR
Heart; 2016 Jan; 102(2):95-9. PubMed ID: 26603680
[TBL] [Abstract][Full Text] [Related]
20. Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis.
Teerlink JR; Davison BA; Cotter G; Maggioni AP; Sato N; Chioncel O; Ertl G; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Edwards C; Senger S; Teichman SL; Nielsen OW; Voors AA; Metra M
Eur J Heart Fail; 2020 Feb; 22(2):315-329. PubMed ID: 31886953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
